Warmuth Markus 4

What Happened

• Markus Warmuth, President & CEO and Director of Monte Rosa Therapeutics (GLUE), sold 9,500 shares on July 16, 2026. The reported weighted-average price was $23.18, with aggregate proceeds of approximately $220,219. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: 2026-07-16 (Form 4 filed 2026-07-17 — filed the next day, which appears timely).
• Price: weighted-average $23.18; prices in the block ranged from $23.18 to $23.23 (footnote says the shares were sold in multiple transactions within that range).
• Type: Sale (reported as "Open market or private sale (S)"); multiple trades aggregated.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnote: Reporting person will provide, upon request, the number of shares sold at each separate price within the $23.18–$23.23 range.
• No 10b5-1 plan, gift, option exercise, or tax-withholding detail was indicated in the filing.

Context

• Sales by executives can be routine (to diversify, cover taxes, or for personal reasons) and do not by themselves prove a change in company outlook. For retail investors, purchases typically carry clearer positive signals than isolated sales.